Quanterix Corp (Quanterix) is a life sciences company that develops and markets an ultra-sensitive digital immunoassay platform. It offers a biomarker detection system, antibodies and ELISA kits, a bead-based immunoassay platform and homebrew assays. Quanterix provides protein biomarker testing and custom assay development services. It markets diagnostics technology under the brands of Simoa, HD-X Analyzer, SR-X, SP-X Imaging and Analysis System and Uman NF-Light. Its products find application in detecting central nervous system (CNS), oncology, and cardiac biomarkers at ultra-low levels; measuring inflammatory markers in normal and disease samples, and cytokine levels and profiles in non-critical and critical COVID-19 patients. The company operates in the Netherlands, Sweden, Hong Kong and China. Quanterix is headquartered in Billerica, Massachusetts, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company Quanterix Corp
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
Quanterix Corp Company Overview
Quanterix Corp Company Snapshot
Quanterix Corp Pipeline Products and Ongoing Clinical Trials Overview
Quanterix Corp – Pipeline Analysis Overview
Quanterix Corp - Key Facts
Quanterix Corp - Major Products and Services
Quanterix Corp Pipeline Products by Development Stage
Ultrasensitive Test - Alzheimer’s Disease Product Overview
Quanterix Corp - Key Competitors
Quanterix Corp - Key Employees
Quanterix Corp - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Quanterix Corp, Recent Developments
May 07, 2024: Quanterix Releases Financial Results for the First Quarter of 2024
Mar 21, 2024: Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
Mar 04, 2024: Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
Feb 26, 2024: Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease
Nov 06, 2023: Quanterix Releases Operating Results for Third Quarter 2023
Oct 24, 2023: Quanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Diseasequanterix Launches High Accuracy P-Tau 217 Blood Biomarker Test to Aid Physician Diagnosis of Alzheimer’s Disease
Aug 07, 2023: Quanterix Releases Operating Results For Second Quarter 2023
Jul 31, 2023: Quanterix’s Simoa Technology Powers Large, International Reference Range Study Utilizing Serum Neurofilament Light (sNfL) to Assess Neurological Disease Activity in Pediatric Patients
Jul 07, 2023: Quanterix introduces new blood test for Alzheimer’s diagnosis
Jul 06, 2023: Quanterix Launches Lucentad Biomarker Blood Test to Aid Physician Diagnosis of Alzheimer’s Disease in Patients